• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks Whale Activity In Today's Session

    6/13/24 1:35:22 PM ET
    $A
    $AGIO
    $CVS
    $GILD
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $A alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    A PUT TRADE BEARISH 07/19/24 $130.00 $620.0K 423 1.0K
    ISRG CALL SWEEP BEARISH 07/19/24 $345.00 $203.3K 88 258
    HIMS CALL TRADE BEARISH 01/17/25 $20.00 $74.8K 12.1K 174
    CVS CALL SWEEP BEARISH 01/16/26 $70.00 $454.7K 26.7K 162
    MDT PUT TRADE BULLISH 08/16/24 $82.50 $29.0K 1.6K 108
    VKTX CALL TRADE BEARISH 01/17/25 $25.00 $29.8K 417 89
    LLY PUT SWEEP BEARISH 11/15/24 $800.00 $31.4K 115 85
    AGIO CALL TRADE BEARISH 07/19/24 $40.00 $39.9K 520 30
    ILMN CALL TRADE NEUTRAL 07/19/24 $110.00 $25.6K 465 5
    GILD CALL TRADE BEARISH 06/21/24 $55.00 $44.0K 72 0

    Explanation

    These bullet-by-bullet explanations have been constructed using the accompanying table.

    • Regarding A (NYSE:A), we observe a put option trade with bearish sentiment. It expires in 36 day(s) on July 19, 2024. Parties traded 2000 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $620.0K, with a price of $310.0 per contract. There were 423 open contracts at this strike prior to today, and today 1041 contract(s) were bought and sold.

    • Regarding ISRG (NASDAQ:ISRG), we observe a call option sweep with bearish sentiment. It expires in 36 day(s) on July 19, 2024. Parties traded 25 contract(s) at a $345.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $203.3K, with a price of $8115.0 per contract. There were 88 open contracts at this strike prior to today, and today 258 contract(s) were bought and sold.

    • Regarding HIMS (NYSE:HIMS), we observe a call option trade with bearish sentiment. It expires in 218 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $74.8K, with a price of $748.0 per contract. There were 12168 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold.

    • Regarding CVS (NYSE:CVS), we observe a call option sweep with bearish sentiment. It expires in 582 day(s) on January 16, 2026. Parties traded 846 contract(s) at a $70.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $454.7K, with a price of $535.0 per contract. There were 26718 open contracts at this strike prior to today, and today 162 contract(s) were bought and sold.

    • For MDT (NYSE:MDT), we notice a put option trade that happens to be bullish, expiring in 64 day(s) on August 16, 2024. This event was a transfer of 108 contract(s) at a $82.50 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $269.0 per contract. There were 1615 open contracts at this strike prior to today, and today 108 contract(s) were bought and sold.

    • For VKTX (NASDAQ:VKTX), we notice a call option trade that happens to be bearish, expiring in 218 day(s) on January 17, 2025. This event was a transfer of 10 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $29.8K, with a price of $2980.0 per contract. There were 417 open contracts at this strike prior to today, and today 89 contract(s) were bought and sold.

    • For LLY (NYSE:LLY), we notice a put option sweep that happens to be bearish, expiring in 155 day(s) on November 15, 2024. This event was a transfer of 11 contract(s) at a $800.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $31.4K, with a price of $2860.0 per contract. There were 115 open contracts at this strike prior to today, and today 85 contract(s) were bought and sold.

    • Regarding AGIO (NASDAQ:AGIO), we observe a call option trade with bearish sentiment. It expires in 36 day(s) on July 19, 2024. Parties traded 50 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $39.9K, with a price of $799.0 per contract. There were 520 open contracts at this strike prior to today, and today 30 contract(s) were bought and sold.

    • For ILMN (NASDAQ:ILMN), we notice a call option trade that happens to be neutral, expiring in 36 day(s) on July 19, 2024. This event was a transfer of 45 contract(s) at a $110.00 strike. The total cost received by the writing party (or parties) was $25.6K, with a price of $570.0 per contract. There were 465 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold.

    • Regarding GILD (NASDAQ:GILD), we observe a call option trade with bearish sentiment. It expires in 8 day(s) on June 21, 2024. Parties traded 50 contract(s) at a $55.00 strike. The total cost received by the writing party (or parties) was $44.0K, with a price of $880.0 per contract. There were 72 open contracts at this strike prior to today, and today 0 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A
    $AGIO
    $CVS
    $GILD

    CompanyDatePrice TargetRatingAnalyst
    Gilead Sciences Inc.
    $GILD
    2/20/2026$155.00Equal Weight
    Barclays
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Medtronic plc.
    $MDT
    2/13/2026$116.00Overweight
    Barclays
    Gilead Sciences Inc.
    $GILD
    2/11/2026$140.00 → $170.00Buy
    Needham
    Medtronic plc.
    $MDT
    2/9/2026$121.00Hold → Buy
    Needham
    Medtronic plc.
    $MDT
    2/3/2026$117.00Buy
    Citigroup
    Medtronic plc.
    $MDT
    1/30/2026$114.00Overweight
    Wells Fargo
    Intuitive Surgical Inc.
    $ISRG
    1/27/2026$660.00Buy
    TD Cowen
    More analyst ratings

    $A
    $AGIO
    $CVS
    $GILD
    SEC Filings

    View All

    Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    2/19/26 6:19:32 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 144 filed by Illumina Inc.

    144 - ILLUMINA, INC. (0001110803) (Subject)

    2/18/26 4:22:07 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Medtronic plc (0001613103) (Filer)

    2/17/26 6:48:07 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $A
    $AGIO
    $CVS
    $GILD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    11/15/24 4:36:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $A
    $AGIO
    $CVS
    $GILD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gottlieb Scott bought $23,562 worth of shares (200 units at $117.81), increasing direct ownership by 2% to 12,723 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    2/11/26 4:04:54 PM ET
    $ILMN
    Medical Specialities
    Health Care

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Gottlieb Scott bought $61,065 worth of shares (500 units at $122.13), increasing direct ownership by 4% to 12,523 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    11/5/25 4:05:20 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $A
    $AGIO
    $CVS
    $GILD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Gilead Sciences with a new price target

    Barclays initiated coverage of Gilead Sciences with a rating of Equal Weight and set a new price target of $155.00

    2/20/26 8:24:53 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays initiated coverage on Eli Lilly with a new price target

    Barclays initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $1,350.00

    2/20/26 8:24:27 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on Medtronic with a new price target

    Barclays resumed coverage of Medtronic with a rating of Overweight and set a new price target of $116.00

    2/13/26 8:31:53 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $A
    $AGIO
    $CVS
    $GILD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

    The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

    2/19/26 5:31:00 PM ET
    $ABBV
    $HCWB
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)

    Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three years  Additional new data revealed exceptionally low surgery and hospitalization rates in Omvoh-treated patients across both Crohn's disease and ulcerative colitis (UC), underscoring its potential to fundamentally change disease trajectory Omvoh now stands alone as the only IL-23p19 inhibitor to show strong and durable efficacy with simple, consistent monthly dosing over four years in UC and three years in Crohn's diseaseINDIANAPOLIS, Feb. 19, 2026 /PRNewswire/ -- New long-term data from Eli Lilly and Company (NYSE:LLY) showed Omvoh (mirikizuma

    2/19/26 12:15:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CVS Pharmacy Partners with U.S. Soccer Federation and National Women's Soccer League to Promote Community Health and Wellness

    Building on its relationship with the Washington Spirit, CVS expands its commitment to soccer through a new multi-year sponsorship with the league and federation, which includes a national community field investment and partnering with the Kansas City Current and Seattle Reign FCWOONSOCKET, R.I., Feb. 19, 2026 /PRNewswire/ -- CVS Pharmacy® has furthered its commitment to improving community health by becoming an Official Health and Wellness Partner of the U.S. Soccer Federation (USSF) and the National Women's Soccer League (NWSL) and is backing that sponsorship with a multi-year investment to develop community multi‑use soccer fields in select markets across the country.

    2/19/26 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $A
    $AGIO
    $CVS
    $GILD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief People Officer Dozier Eric gifted 481 shares, decreasing direct ownership by 3% to 14,455 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/19/26 4:18:48 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $66.64 and sold $4,324,228 worth of shares (28,000 units at $154.44), decreasing direct ownership by 2% to 120,288 units (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    2/18/26 5:22:54 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Dickinson Andrew D sold $463,290 worth of shares (3,000 units at $154.43), decreasing direct ownership by 2% to 167,779 units (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    2/18/26 5:11:41 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $A
    $AGIO
    $CVS
    $GILD
    Financials

    Live finance-specific insights

    View All

    Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

    – Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from the PURPOSE Program Further Demonstrates the Safety and Efficacy Profile of Twice-Yearly Lenacapavir for HIV Prevention – Gilead Sciences, Inc. (NASDAQ:GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) being held from February 22-25 in Denver, Colorado. Focusing on expanding therapeutic options to meet the diverse needs of communities af

    2/17/26 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters

    Cardiovascular portfolio up 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolioGALWAY, Ireland, Feb. 17, 2026 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its third quarter (Q3) of fiscal year 2026 (FY26), which ended January 23, 2026.Q3 Key HighlightsRevenue of $9.0 billion, increased 8.7% as reported and 6.0% organic, 50 basis points ahead of Q3 guidanceGAAP diluted EPS of $0.89; non-GAAP diluted EPS of $1.36, three cents ahead of Q3 guidance mid-pointCompany reiterates FY26 organic revenue growth and EPS guidanceCardiac Ablation Solutions revenue increased 80%, includin

    2/17/26 6:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    PYRUKYND® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full yearAQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approvalCompany will have pre-sNDA meeting with FDA for mitapivat in sickle cell disease in first quarter of 2026Phase 2 tebapivat trial in sickle cell disease fully enrolled; topline results expected in second half of 2026$1.2 billion dollars in cash, cash equivalents, and marketable securities as of December 31, 2025 CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patie

    2/12/26 6:30:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $A
    $AGIO
    $CVS
    $GILD
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Illumina Appoints Dr. Eric Green as Chief Medical Officer

    Veteran genomics leader joins Illumina to advance global medical strategyIllumina chief commercial officer to depart for role as a life science tools company CEO  SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ:ILMN) announced the appointment of Eric D. Green, M.D., Ph.D., as Chief Medical Officer (CMO), effective February 2. In this role reporting to the CEO, Dr. Green will accelerate the company's mission to drive a revolution in medicine by unlocking the power of the genome. Dr. Green will serve as a key scientific and medical leader representing Illumina, helping advance the clinical use of genomics, expand access to precision medicine solutions, and increase the di

    1/8/26 4:30:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $A
    $AGIO
    $CVS
    $GILD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care